Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) today announced a collaboration to discover and develop RNA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Management Comments

Dicerna Pharma (DRNA) Highlights Late-Breaking Data Supporting Use of DCR-PHXC in Adults with Primary Hyperoxaluria Types 1 and 2 (PH1 and PH2)October 25, 2018 1:21 PM Alexion Pharma (ALXN) Tops Q3 EPS by 28c, Revenues Beat; Boosts FY18 EPS/Revenue/Operating Margin OutlookOctober 24, 2018 6:38 AM Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated DiseasesOctober 24, 2018 6:30 AM